English

THRESHOLD PHARMACEUTICALS INC

EDGAR

MTEM Quarterly report (10-Q) · filed 2024-08-14

98 filing records in this dataset, filed from 2005-03-31 to 2024-08-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

6.75 million USD

2018 Q3 · USD

Exact inputs and evidence

Revenue: 6752000 USD Source

Operating margin

-75.18%

2018-09-30 · %

Exact inputs and evidence

Operating Income: -24204000 USD Source
Operating Income: -19128000 USD Source
Revenue: 6752000 USD Source

Operating cash flow

-9.72 million USD

2018 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -23859000 USD Source
Operating Cash Flow: -14136000 USD Source

Free cash flow

-11 million USD

2018 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -23859000 USD Source
Operating Cash Flow: -14136000 USD Source
Capital Expenditure: 5421000 USD Source
Capital Expenditure: 4190000 USD Source

Cash and cash equivalents: 9.7 million Unit_Standard_USD_BTtiQyljdEiM84kstGoYsA 2024-06-30 Source
Exact value

9700000 Unit_Standard_USD_BTtiQyljdEiM84kstGoYsA
Long-term debt including current maturities: 36.4 million USD 2023-03-31 Source
Exact value

36400000 USD
Shares outstanding: 6.58 million Unit_Standard_shares_xQH5TFip1UWs7Nua6Om2ew 2024-06-30 Source
Exact value

6583880 Unit_Standard_shares_xQH5TFip1UWs7Nua6Om2ew

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

9.42 million USD

2017-10-01 – 2018-09-30

Exact inputs and evidence

Revenue: 3395000 USD · 2017-01-01 – 2017-12-31 Source
Revenue: 2575000 USD · 2017-01-01 – 2017-09-30 Source
Revenue: 482000 USD · 2018-01-01 – 2018-03-31 Source
Revenue: 1367000 USD · 2018-04-01 – 2018-06-30 Source
Revenue: 6752000 USD · 2018-07-01 – 2018-09-30 Source

Net income

-60.3 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Net income: -24420000 USD · 2022-04-01 – 2022-06-30 Source
Net income: -70669000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -46031000 USD · 2022-01-01 – 2022-06-30 Source
Net income: -92718000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -70669000 USD · 2022-01-01 – 2022-09-30 Source
Net income: 10845000 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-08-14.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2017-12-31
Operating income: 2 of 11 periods available· newest 2023-12-31
Net income: 2 of 11 periods available· newest 2023-12-31
Operating cash flow: 2 of 11 periods available· newest 2023-12-31
Capital expenditure: 2 of 11 periods available· newest 2023-12-31
Total assets: Multiple units; comparison withheld· newest 2023-12-31
Total liabilities: Multiple units; comparison withheld· newest 2023-12-31
Current assets: Multiple units; comparison withheld· newest 2023-12-31
Current liabilities: Multiple units; comparison withheld· newest 2023-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2023-12-31
Long-term debt including current maturities: 7 of 11 periods available· newest 2022-12-31
Shares outstanding: Multiple units; comparison withheld· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 84.59 million

Prior period

−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 92.72 million

2022-01-01 – 2022-12-31
Current period

−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 8.12 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-8124000 − -92718000 = 84594000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw

-92718000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-8124000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · THRESHOLD PHARMACEUTICALS INC · 2023-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Year-over-year change in Net income: 84594000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -8124000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1539732 Filing: 000155837024004332 Input fundies:NetIncome: -92718000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1491143 Filing: 000155837024004332
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 47.2 million

Prior period

−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 89.02 million

2022-01-01 – 2022-12-31
Current period

−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 41.82 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-41820000 − -89024000 = 47204000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw

-89024000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-41820000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · THRESHOLD PHARMACEUTICALS INC · 2023-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Year-over-year change in Operating cash flow: 47204000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -41820000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1598403 Filing: 000155837024004332 Input fundies:OperatingCashFlow: -89024000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1599419 Filing: 000155837024004332
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-93.7%

Prior period

Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 3.2 million

2022-01-01 – 2022-12-31
Current period

Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 200,000

2023-01-01 – 2023-12-31

Exact inputs and evidence

200000 − 3198000 = -2998000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw

3198000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
200000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · THRESHOLD PHARMACEUTICALS INC · 2023-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Year-over-year change in Capital expenditure: -2998000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 200000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1602317 Filing: 000155837024004332 Input fundies:CapitalExpenditure: 3198000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1603257 Filing: 000155837024004332
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue USD 3.4 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow Unavailable An input is unavailable.
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	1880000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2016-01-01 – 2016-12-31: 1880000 USD Inspect Revenue Open source
2017 2017-01-01 – 2017-12-31	3395000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2017-01-01 – 2017-12-31: 3395000 USD Inspect Revenue Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 3.4M 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	1880000	Revenue: 1880000 Open source
20172017-12-31	Revenue	3395000	Revenue: 3395000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

80.6% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 1880000 Open source
20172017-12-31	Year over year	80.6%	Revenue: 3395000 Open source Revenue: 1880000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Operating margin	Not reported	Revenue: 1880000 Open source
2017-12-31	Operating margin	Not reported	Revenue: 3395000 Open source
2016-12-31	Net margin	Not reported	Revenue: 1880000 Open source
2017-12-31	Net margin	Not reported	Revenue: 3395000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 1880000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 3395000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	Not reported	No source recorded
20172017-12-31	Operating cash flow	Not reported	No source recorded

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Free cash flow	Unavailable	No source recorded
20172017-12-31	Free cash flow	Unavailable	No source recorded

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	No source recorded
2017-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
2017-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2022 2022-01-01 – 2022-12-31	−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 92.72 million Exact value Exact value: -92718000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 2022-01-01 – 2022-12-31: -92718000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Inspect Net Income Open source Share or cite Citation for Net Income · THRESHOLD PHARMACEUTICALS INC · 2022-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Net Income: -92718000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw&dimensions= Input fundies:NetIncome: -92718000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1491143 Filing: 000155837024004332 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 89.02 million Exact value Exact value: -89024000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 2022-01-01 – 2022-12-31: -89024000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · THRESHOLD PHARMACEUTICALS INC · 2022-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Operating Cash Flow: -89024000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw&dimensions= Input fundies:OperatingCashFlow: -89024000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1599419 Filing: 000155837024004332 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 3.2 million Exact value Exact value: 3198000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 2022-01-01 – 2022-12-31: 3198000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · THRESHOLD PHARMACEUTICALS INC · 2022-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Capital Expenditure: 3198000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw&dimensions= Input fundies:CapitalExpenditure: 3198000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1603257 Filing: 000155837024004332 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 92.22 million Calculation and evidence -89024000 − 3198000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Exact free cash flow: -92222000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 2022-01-01 – 2022-12-31: -89024000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 3198000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · THRESHOLD PHARMACEUTICALS INC · 2022-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Free cash flow: -92222000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -89024000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1599419 Filing: 000155837024004332 Input fundies:CapitalExpenditure: 3198000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1603257 Filing: 000155837024004332 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 8.12 million Exact value Exact value: -8124000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 2023-01-01 – 2023-12-31: -8124000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Inspect Net Income Open source Share or cite Citation for Net Income · THRESHOLD PHARMACEUTICALS INC · 2023-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Net Income: -8124000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw&dimensions= Input fundies:NetIncome: -8124000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1539732 Filing: 000155837024004332 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 41.82 million Exact value Exact value: -41820000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 2023-01-01 – 2023-12-31: -41820000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · THRESHOLD PHARMACEUTICALS INC · 2023-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Operating Cash Flow: -41820000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw&dimensions= Input fundies:OperatingCashFlow: -41820000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1598403 Filing: 000155837024004332 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 200,000 Exact value Exact value: 200000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 2023-01-01 – 2023-12-31: 200000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · THRESHOLD PHARMACEUTICALS INC · 2023-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Capital Expenditure: 200000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw&dimensions= Input fundies:CapitalExpenditure: 200000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1602317 Filing: 000155837024004332 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 42.02 million Calculation and evidence -41820000 − 200000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Exact free cash flow: -42020000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw 2023-01-01 – 2023-12-31: -41820000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 200000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · THRESHOLD PHARMACEUTICALS INC · 2023-12-31 THRESHOLD PHARMACEUTICALS INC (edgar:1183765) Free cash flow: -42020000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1183765?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41820000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1598403 Filing: 000155837024004332 Input fundies:CapitalExpenditure: 200000 Unit_Standard_USD_46dVh-ChSku9WFmDyniiSw (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1183765/000155837024004332/mtem-20231231x10k.htm#1602317 Filing: 000155837024004332 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

98 filings · 3,726 latest values · 3,726 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001183765, 1183765, MTEM, THLD, edgar:1183765

Also known as MOLECULAR TEMPLATES, INC., Molecular Templates, Inc., Molecular Templates, Inc., THRESHOLD PHARMACEUTICALS INC

THRESHOLD PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation